Earnings Review
Alkem Lab Q3 consol PAT growth slowest in 11 quarters
This story was originally published at 15:56 IST on 13 February 2026
Register to read our real-time news.Informist, Friday, Feb. 13, 2026
Please click here to read all liners published on this story
--Alkem Lab: US business sales contributed 20.3% to total sales in Oct-Dec
--Alkem Lab Oct-Dec non-US ops revenue INR 4.62 bln, up 41.6% on yr
--Alkem Lab Oct-Dec US revenue INR 7.53 bln, up 18.8% on year
--Alkem Lab Oct-Dec consol R&D expenses INR 1.39 bln, 3.7% of total sales
--Alkem Lab Oct-Dec consol R&D expenses INR 1.39 bln vs INR 1.31 bln yr ago
--Alkem Lab Oct-Dec international revenue INR 12.16 bln, up 26.6% on yr
--Alkem Lab Oct-Dec India revenue INR 24.96 bln, up 5.5% on year
--Alkem Lab: To launch GLP-1 semaglutide in Mar, seen to be key growth driver
--Alkem Lab: On track to deliver FY25 guidance
--Alkem Lab Oct-Dec consol gross profit margin 65.9% vs 64.3% year ago
--Alkem Lab Oct-Dec consol EBITDA margin 22.2% vs 22.5% year ago
--Alkem Lab Oct-Dec consol EBITDA INR 8.28 bln vs INR 7.59 bln yr ago
--Alkem Lab Oct-Dec profit excluding labour code impact INR 6.89 bln
--Alkem Lab Oct-Dec labour code implementation cost INR 527.90 mln
--Alkem Lab Apr-Dec consol revenue INR 111.09 bln vs INR 98.21 bln year ago
--Alkem Lab Apr-Dec consol PAT INR 20.65 bln vs INR 18.60 bln year ago
--Alkem Lab interim dividend record date Feb 20
--Alkem Lab to pay INR 43 per share interim dividend
--Alkem Lab Oct-Dec consol revenue INR 37.37 bln vs INR 33.74 bln year ago
--Alkem Lab Oct-Dec consol PAT INR 6.36 bln vs INR 6.26 bln year ago
--Analysts saw Alkem Lab Oct-Dec consol revenue at INR 37.32 bln
--Alkem Lab Oct-Dec consol revenue INR 37.37 bln
--Analysts saw Alkem Lab Oct-Dec consol net profit at INR 6.06 bln
--Alkem Lab Oct-Dec consol net profit INR 6.36 bln
By Narayana Krishna
HYDERABAD – Alkem Laboratories Ltd. on Friday reported a consolidated net profit of INR 6.36 billion for the December quarter, up 1.6% on year but down nearly 17% on quarter. The net profit growth was the slowest in 11 quarters.
The company's revenue for the quarter rose nearly 11% year on year but fell nearly 7% on quarter to INR 37.37 billion. Both the net profit and revenue were in line with analysts' estimates. Analysts had estimated Alkem Lab's net profit at INR 6.06 billion and revenue was projected at INR 37.32 billion.
"In Q3 (Oct-Dec), we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses," Vikas Gupta, chief executive officer of the company, said in a press release.
The company reported a one-time cost of INR 527.90 million related to implementation of the new labour codes. If this cost is excluded, the company's net profit would have been INR 6.89 billion.
"We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets," Alkem Lab said.
Alkem Lab had guided for double-digit growth in the US and exceeding the Indian pharmaceutical market's growth in 2025-26 (Apr-Mar). The company's India revenue in the December quarter rose 5.5% on year to INR 24.96 billion and its international business rose 26.6% on year to INR 12.16 billion.
US sales for the December quarter grew 18.8% on year to INR 7.53 billion, accounting for 20.3% of the total sales. The non-US markets reported 41.6% on-year growth for the quarter to INR 4.62 billion.
Alkem Lab's gross margin improved to 65.9% from 64.3% a year ago. Its earnings before interest, tax, depreciation, and amortisation margin grew 22.2% in the December quarter, against a growth of 22.5% a year ago. The EBITDA for the quarter improved to INR 8.28 billion from INR 7.59 billion a year ago. The company had guided an EBITDA margin of 19.5-20.0% for FY26.
The company's total expenses for the December quarter were up 11.3% on year at INR 30.5 billion. Input costs for the quarter up 1.5% on year at INR 9.4 billion. Other expenses up by 16.4% on year at INR 9.1 billion. The employee expenses rose 15.5% on year to INR 7.2 billion. The company's research and development spend was INR 1.39 billion, 3.7% of the total sales.
For Apr-Dec, the company reported a consolidated net profit of INR 20.65 billion on a revenue of INR 111.09 billion. The board of Alkem Lab Friday approved an interim dividend of INR 43 per share and set Feb. 20 as the record date.
On the National Stock Exchange, shares of the company closed nearly 8% lower at INR 5,402.50. End
Edited by Ashish Shirke
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
